An aim of the study was to evaluate the therapeutic effect of neyromidin in patients with ischemic stroke. Forty patients with acute carotid artery stroke were enrolled into the study. The diagnosis was made on the basis of general clinical methods as well as the neurological examination, CT or MRI scans of the head, investigation of hemodynamic parameters, ECG, ultrasound dopplerography of major brain arteries. Neurological deficit was measured using the Scandinavian Scale. According to the TOAST classification, 14 (35%) of the patients suffered from large vessel disease, 16 (40%) patients were diagnosed with cardioembolic disease and 10 (25%) with the small vessel disease. Patients were randomized to the study and control groups (n=20 patients). All patients received standard treatment. Patients of the study group were treated with neyromidin. The study duration was 80 days. Clinical examinations were performed in the acute phase, on 21st and 80th days after stroke. Better recovery of neurological functions was identified in patients treated with neyromidin compared to control patients. No side-effects of neyromidin was found. Neyromidin is recommended for complex treatment of patients in the acute stage of ischemic stroke of carotid origin.